title: Challenges ahead for companion diagnostics.
authors.forename: Charlie
authors.initials: C
authors.lastname: Schmidt
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D000077547:Crizotinib; D057069:Diagnostic Test Approval / Q000592:standards / Q000639:trends; D017277:Drug Approval; D004348:Drug Labeling; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy; D058990:Molecular Targeted Therapy / Q000639:trends*; D009154:Mutation; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D018579:Patient Selection; D057285:Precision Medicine / Q000639:trends*; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011720:Pyrazoles; D011725:Pyridines; D013449:Sulfonamides; D000077484:Vemurafenib; D000077547:Crizotinib